Étude dosimétrique de préparations de médicaments radiopharmaceutiques au 68Ga

Abstract

AimProduction of 68Ga-radiopharmaceuticals is a rapidly growing field in France. However, operators may already be involved in other radiopharmaceutical activities. It is thus necessary to know the exposure of this new activity. Material and methodsFor passive dosimetry, a radiophotoluminescent (RPL) dosimeter, a thermoluminescent (TLD) chip, 2 TLD rings and a passive dosimeter for crystalline were used. For active dosimetry, an extremity dosimeter and a whole body dosimeter were used. This study was performed during semi-automatized production of 68Ga-investigational medicinal products. Values were normalized to 500MBq manipulated (median activity using a 1850MBq 68Ga-generator), 60 radiosynthesis (maximum enrollment ability of our center) and 2 operators. A LB123 proportional counter was used for quantification of external exposition to 10MBq 68Ge and internal exposition by inhalation was theoretically assessed. 68Ga emission attenuation by collective protection equipments was also discussed. ResultsConsidering passive dosimetry, the equivalent dose to extremities was 21.75±0.34mSv, the whole-body effective dose was 0.189±0.011mSv and the dose to crystalline was 0.925±0.009mSv. Considering active dosimetry, the equivalent dose to extremities was 8,75±0.12mSv and the whole-body effective dose was 0,088±0.009mSv. Total exposure to 68Ge was 1.75μSv. ConclusionIn our hands, 68Ga is a directly transposable activity in radiopharmacies already equipped for 18F because of a dosimetry complying with regulatory limits and suitable radiation protection of collective equipments.